Cargando…
Hypertensive Rats Treated Chronically With N(ω)-Nitro-L-Arginine Methyl Ester (L-NAME) Induced Disorder of Hepatic Fatty Acid Metabolism and Intestinal Pathophysiology
N(ω)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) biosynthesis, results in hypertension and liver injury. This study aimed at investigating the changes of liver lipometabonomics and exploring the underlying mechanisms of liver injury in the L-NAME-treated rats. The male...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006817/ https://www.ncbi.nlm.nih.gov/pubmed/32076406 http://dx.doi.org/10.3389/fphar.2019.01677 |
_version_ | 1783495214018592768 |
---|---|
author | Li, Bo He, Xinglishang Lei, Shan-Shan Zhou, Fu-Chen Zhang, Ning-Yu Chen, Ye-Hui Wang, Yu-Zhi Su, Jie Yu, Jing-Jing Li, Lin-Zi Zheng, Xiang Luo, Rong Kołodyńska, Dorota Xiong, Shan Lv, Gui-Yuan Chen, Su-Hong |
author_facet | Li, Bo He, Xinglishang Lei, Shan-Shan Zhou, Fu-Chen Zhang, Ning-Yu Chen, Ye-Hui Wang, Yu-Zhi Su, Jie Yu, Jing-Jing Li, Lin-Zi Zheng, Xiang Luo, Rong Kołodyńska, Dorota Xiong, Shan Lv, Gui-Yuan Chen, Su-Hong |
author_sort | Li, Bo |
collection | PubMed |
description | N(ω)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) biosynthesis, results in hypertension and liver injury. This study aimed at investigating the changes of liver lipometabonomics and exploring the underlying mechanisms of liver injury in the L-NAME-treated rats. The male Sprague-Dawley (SD) rats were treated with L-NAME (40 mg/kg, p.o.) for 8 weeks. After that, the liver, aorta, fecal, and serum were collected for analysis. The results showed that L-NAME induced hypertension and disordered the endothelial nitric oxide synthase (eNOS)-NO pathway in the treated rats. L-NAME could also increase the levels of serum total cholesterol (TC), triglyceride (TG), alanine transaminase (ALT), and aspartate transaminase (AST). The multidimensional mass spectrometry-based shotgun lipidomics (MDMS-SL) analysis showed that L-NAME could induce significant changes of the total hepatic lipids and most hepatic triglycerides, as well as fatty acid (FA). A positive correlation was found between the blood pressure and TAG. Immunofluorescence and Western-Blot experiments indicated that the L-NAME treatment significantly influenced some FA β-oxidation, desaturation, and synthesis-related proteins. The increase of intestinal inflammation, decrease of microcirculation and tight junction proteins, as well as alterations of microbial communities were observed in the L-NAME induced hypertensive rats, as well as alterations of microbial communities were notable correlation to TAG and FA species. This study demonstrated that the L-NAME-induced hypertensive rats exhibiting liver injury were the joint action of hepatic abnormal fatty acid metabolism and microcirculation disorder. Furthermore, the gut microflora, as well as the changes of FA β-oxidation (ACOX, CPT1α), desaturation (SCD-1), and synthesis (FAS) may be the potential mechanisms for abnormal fatty acid metabolism. |
format | Online Article Text |
id | pubmed-7006817 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-70068172020-02-19 Hypertensive Rats Treated Chronically With N(ω)-Nitro-L-Arginine Methyl Ester (L-NAME) Induced Disorder of Hepatic Fatty Acid Metabolism and Intestinal Pathophysiology Li, Bo He, Xinglishang Lei, Shan-Shan Zhou, Fu-Chen Zhang, Ning-Yu Chen, Ye-Hui Wang, Yu-Zhi Su, Jie Yu, Jing-Jing Li, Lin-Zi Zheng, Xiang Luo, Rong Kołodyńska, Dorota Xiong, Shan Lv, Gui-Yuan Chen, Su-Hong Front Pharmacol Pharmacology N(ω)-nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide (NO) biosynthesis, results in hypertension and liver injury. This study aimed at investigating the changes of liver lipometabonomics and exploring the underlying mechanisms of liver injury in the L-NAME-treated rats. The male Sprague-Dawley (SD) rats were treated with L-NAME (40 mg/kg, p.o.) for 8 weeks. After that, the liver, aorta, fecal, and serum were collected for analysis. The results showed that L-NAME induced hypertension and disordered the endothelial nitric oxide synthase (eNOS)-NO pathway in the treated rats. L-NAME could also increase the levels of serum total cholesterol (TC), triglyceride (TG), alanine transaminase (ALT), and aspartate transaminase (AST). The multidimensional mass spectrometry-based shotgun lipidomics (MDMS-SL) analysis showed that L-NAME could induce significant changes of the total hepatic lipids and most hepatic triglycerides, as well as fatty acid (FA). A positive correlation was found between the blood pressure and TAG. Immunofluorescence and Western-Blot experiments indicated that the L-NAME treatment significantly influenced some FA β-oxidation, desaturation, and synthesis-related proteins. The increase of intestinal inflammation, decrease of microcirculation and tight junction proteins, as well as alterations of microbial communities were observed in the L-NAME induced hypertensive rats, as well as alterations of microbial communities were notable correlation to TAG and FA species. This study demonstrated that the L-NAME-induced hypertensive rats exhibiting liver injury were the joint action of hepatic abnormal fatty acid metabolism and microcirculation disorder. Furthermore, the gut microflora, as well as the changes of FA β-oxidation (ACOX, CPT1α), desaturation (SCD-1), and synthesis (FAS) may be the potential mechanisms for abnormal fatty acid metabolism. Frontiers Media S.A. 2020-01-31 /pmc/articles/PMC7006817/ /pubmed/32076406 http://dx.doi.org/10.3389/fphar.2019.01677 Text en Copyright © 2020 Li, He, Lei, Zhou, Zhang, Chen, Wang, Su, Yu, Li, Zheng, Luo, Kołodyńska, Xiong, Lv and Chen http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Li, Bo He, Xinglishang Lei, Shan-Shan Zhou, Fu-Chen Zhang, Ning-Yu Chen, Ye-Hui Wang, Yu-Zhi Su, Jie Yu, Jing-Jing Li, Lin-Zi Zheng, Xiang Luo, Rong Kołodyńska, Dorota Xiong, Shan Lv, Gui-Yuan Chen, Su-Hong Hypertensive Rats Treated Chronically With N(ω)-Nitro-L-Arginine Methyl Ester (L-NAME) Induced Disorder of Hepatic Fatty Acid Metabolism and Intestinal Pathophysiology |
title | Hypertensive Rats Treated Chronically With N(ω)-Nitro-L-Arginine Methyl Ester (L-NAME) Induced Disorder of Hepatic Fatty Acid Metabolism and Intestinal Pathophysiology |
title_full | Hypertensive Rats Treated Chronically With N(ω)-Nitro-L-Arginine Methyl Ester (L-NAME) Induced Disorder of Hepatic Fatty Acid Metabolism and Intestinal Pathophysiology |
title_fullStr | Hypertensive Rats Treated Chronically With N(ω)-Nitro-L-Arginine Methyl Ester (L-NAME) Induced Disorder of Hepatic Fatty Acid Metabolism and Intestinal Pathophysiology |
title_full_unstemmed | Hypertensive Rats Treated Chronically With N(ω)-Nitro-L-Arginine Methyl Ester (L-NAME) Induced Disorder of Hepatic Fatty Acid Metabolism and Intestinal Pathophysiology |
title_short | Hypertensive Rats Treated Chronically With N(ω)-Nitro-L-Arginine Methyl Ester (L-NAME) Induced Disorder of Hepatic Fatty Acid Metabolism and Intestinal Pathophysiology |
title_sort | hypertensive rats treated chronically with n(ω)-nitro-l-arginine methyl ester (l-name) induced disorder of hepatic fatty acid metabolism and intestinal pathophysiology |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006817/ https://www.ncbi.nlm.nih.gov/pubmed/32076406 http://dx.doi.org/10.3389/fphar.2019.01677 |
work_keys_str_mv | AT libo hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT hexinglishang hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT leishanshan hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT zhoufuchen hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT zhangningyu hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT chenyehui hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT wangyuzhi hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT sujie hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT yujingjing hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT lilinzi hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT zhengxiang hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT luorong hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT kołodynskadorota hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT xiongshan hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT lvguiyuan hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology AT chensuhong hypertensiveratstreatedchronicallywithnōnitrolargininemethylesterlnameinduceddisorderofhepaticfattyacidmetabolismandintestinalpathophysiology |